Frontlight ResearchEarly access
Thyroid cancer trials in Italy
10 of 22 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Not yet taking people in ItalyPhase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Where
- Milan, Rome, Rozzano
- Age
- 18 years and over
- People
- 554 worldwide
- Run by
- Institut de Recherches Internationales Servier
See details and how to joinNCT05786924 · EU 2025-523474-16-00 - No phaseTaking peopleCross Immune Response Between Breast Carcinoma and Thyroid Autoimmunity: Impact on Prognosis and Treatment
- Where
- Milan
- Age
- 18 years to 80 years
- People
- 496
- Run by
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
See details and how to joinNCT07870148 - Phase 1Not yet taking people in ItalyPhase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
- Where
- Milan, Naples
- Age
- 18 years to 100 years
- People
- 116 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00 - Phase 2Taking peopleA Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Where
- Meldola, Milan, Naples
- Age
- 8 years and over
- People
- 254 worldwide
- Run by
- Fore Biotherapeutics
See details and how to joinNCT05503797 · EU 2024-513578-23-00 - Phase 4Not yet taking people in ItalyProspective, multicenter, randomized study on combined LT4 + LT3 therapy versus LT4 in the control of TSH in patients with advanced thyroid cancer treated with tyrosine kinase inhibitors.
- Where
- Catania, Milan, Naples, Padova, Pavia, Perugia, Pisa, Rome, Salerno, Siena
- Age
- 18 years and over
- People
- 110
- Run by
- Ceinge Biotecnologie Avanzate Franco Salvatore S.c.a.r.l.
See details and how to join2026-526113-28-00 - Phase 1/2Active, not recruitingA Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
- Where
- Aviano, Milan, Rome
- Age
- 12 years and over
- People
- 500 worldwide
- Run by
- Turning Point Therapeutics, Inc.
See details and how to joinNCT03093116 · EU 2024-512606-25-00 - Phase 2Taking peoplePembrolizumab in High-risk Thyroid Cancer
- Where
- Milan, Pavia, Rome
- Age
- 18 years to 64 years
- People
- 25
- Run by
- Istituti Clinici Scientifici Maugeri SpA
See details and how to joinNCT05852223 · EU 2024-519129-38-00 - No phaseTaking peopleEMDR Integrative Group Protocol and Individual Treatment for Patients With Cancer: A Pilot Study
- Where
- Milan
- Age
- 18 years to 100 years
- People
- 25
- Run by
- Università Cattolica di Milano
See details and how to joinNCT07447089 - Phase 2Taking peopleAPL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- Where
- Ancona, Bologna, Meldola, Milan, Padova, Turin
- Age
- 18 years and over
- People
- 497 worldwide
- Run by
- Apollomics Inc.
See details and how to joinNCT03175224 · EU 2024-514542-37-00 - Phase 3Taking peopleTSH Suppression During Radiotherapy on Thyroid Site to Prevent Iatrogenic Hypothyroidism in Pediatric Cancer Patients
- Where
- Milan
- People
- 68
- Run by
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
See details and how to joinNCT05316922